HFCAS OpenIR
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Sun, Yongkun1; Zhang, Wen1; Bi, Xinyu2; Yang, Zhengqiang3; Tang, Yu4; Jiang, Liming5; Bi, Feng6; Chen, Minshan7; Cheng, Shuqun8; Chi, Yihebali1; Han, Yue3; Huang, Jing1; Huang, Zhen2; Ji, Yuan9; Jia, Liqun10; Jiang, Zhichao1; Jin, Jing11; Jin, Zhengyu12; Li, Xiao3; Li, Zhiyu2; Liang, Jun13; Liu, Lianxin14; Liu, Yunpeng15; Lu, Yinying16; Lu, Shichun17; Meng, Qinghua18; Niu, Zuoxing19; Pan, Hongming20; Qin, Shukui21; Qu, Wang1; Shao, Guoliang22; Shen, Feng23; Song, Tianqiang24; Song, Yan1; Tao, Kaishan25; Tian, Aiping26; Wang, Jianhua27; Wang, Wenling28; Wang, Zhe29; Wu, Liqun30; Xia, Feng31; Xing, Baocai32; Xu, Jianming33; Xue, Huadan12; Yan, Dong3; Yang, Lin1; Ying, Jianming34; Yun, Jingping35; Zeng, Zhaochong36; Zhang, Xuewen37; Zhang, Yanqiao38; Zhang, Yefan2; Zhao, Jianjun2; Zhou, Jianguo2; Zhu, Xu39; Zou, Yinghua40; Dong, Jiahong41; Fan, Jia42; Lau, Wan Yee43; Sun, Yan1; Yu, Jinming44; Zhao, Hong2; Zhou, Aiping1; Cai, Jianqiang2
2022-06-01
Source PublicationLIVER CANCER
ISSN2235-1795
Corresponding AuthorZhao, Hong(zhaohong@cicams.ac.cn) ; Zhou, Aiping(aiping_zhou@yeah.net) ; Cai, Jianqiang(caijianqiang188@sina.com)
AbstractBackground: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.
KeywordChinese interdisciplinary experts Hepatocellular carcinoma Molecular targeted therapy Consensus
DOI10.1159/000521596
WOS KeywordVEIN TUMOR THROMBUS ; TRANSARTERIAL CHEMOEMBOLIZATION ; LIVER-TRANSPLANTATION ; DOUBLE-BLIND ; 1ST-LINE TREATMENT ; PLUS SORAFENIB ; OPEN-LABEL ; PHASE-III ; EFFICACY ; SAFETY
Indexed BySCI
Language英语
Funding ProjectState Key Project on Infection Diseases of China[2017ZX10201021-007-003] ; CAMS Innovation Fund for Medical Sciences (CIFMS)[2017-12M-4-002] ; Non-profit Central Research Institution Fund of Chinese Academy of Medical Sciences[2019PT310026] ; Sanming Project of Medicine in Shenzhen[SZSM202011010] ; Capital Health Research and Development of Special[2018-1-4021]
Funding OrganizationState Key Project on Infection Diseases of China ; CAMS Innovation Fund for Medical Sciences (CIFMS) ; Non-profit Central Research Institution Fund of Chinese Academy of Medical Sciences ; Sanming Project of Medicine in Shenzhen ; Capital Health Research and Development of Special
WOS Research AreaOncology ; Gastroenterology & Hepatology
WOS SubjectOncology ; Gastroenterology & Hepatology
WOS IDWOS:000840263800002
PublisherKARGER
Citation statistics
Cited Times:25[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.hfcas.ac.cn:8080/handle/334002/132072
Collection中国科学院合肥物质科学研究院
Corresponding AuthorZhao, Hong; Zhou, Aiping; Cai, Jianqiang
Affiliation1.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
2.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Hepatobiliary Surg, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
3.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Intervent Radiol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
4.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept GCP Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
5.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Diagnost Imaging, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
6.West China Hosp, Dept Med Oncol, Chengdu, Peoples R China
7.Sun Yat Sen Univ Canc Ctr, Dept Hepatobiliary Oncol, Guangzhou, Peoples R China
8.Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China
9.Fudan Univ, Dept Pathol, Zhongshan Hosp, Shanghai, Peoples R China
10.China Japan Friendship Hosp, Dept Oncol Integrat Chinese & Western Med, Beijing, Peoples R China
11.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Radiol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
12.Peking Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China
13.Peking Univ Int Hosp, Dept Med Oncol, Beijing, Peoples R China
14.Univ Sci & Technol China, Dept Hepat Surg, Affiliated Hosp 1, Hefei, Peoples R China
15.China Med Univ, Dept Med Oncol, Affiliated Hosp 1, Shenyang, Peoples R China
16.Chinese Peoples Liberat Army Gen Hosp, Dept Comprehens Liver Canc Ctr, Med Ctr 5, Beijing, Peoples R China
17.Chinese PLA Med Sch, Chinese Peoples Liberat Army PLA Gen Hosp, Dept Hepatobiliary Surg, Med Ctr 1, Beijing, Peoples R China
18.Capital Med Univ, Beijing Youan Hosp, Dept Clin Care Med Liver Dis, Beijing, Peoples R China
19.Shandong Canc Hosp & Inst, Dept Med Oncol, Jinan, Peoples R China
20.Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Dept Med Oncol, Hangzhou, Peoples R China
21.Nanjing Bayi Hosp, Dept Med Oncol, PLA Canc Ctr, Nanjing, Peoples R China
22.Univ Chinese Acad Sci, Dept Intervent Radiol, Canc Hosp, Hangzhou, Peoples R China
23.Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg Iv, Shanghai, Peoples R China
24.Tianjin Med Univ Canc Inst & Hosp, Dept Hepatobiliary Surg, Tianjin, Peoples R China
25.Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Peoples R China
26.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Tradit Chinese Med, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
27.Fudan Univ, Dept Intervent Radiol, Zhongshan Hosp, Shanghai, Peoples R China
28.Guizhou Med Univ, Guizhou Canc Hosp, Dept Radiol, Affiliated Hosp, Guiyang, Peoples R China
29.Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian, Peoples R China
30.Qingdao Univ, Dept Hepat Biliary Pancreat Surg, Affiliated Hosp, Qingdao, Peoples R China
31.AMU, Dept Hepatobiliary Surg, Southwest Hosp, Chongqing, Peoples R China
32.Beijing Canc Hosp, Dept Hepatobiliary & Pancreat Surg Unit 1, Beijing, Peoples R China
33.Chinese Peoples Liberat Army Gen Hosp, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China
34.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Pathol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
35.Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China
36.Fudan Univ, Dept Radiol, Zhongshan Hosp, Shanghai, Peoples R China
37.Second Hosp Jilin Univ, Dept Hepatobiliary & Pancreat Surg, Changchun, Jilin, Peoples R China
38.Harbin Med Univ Canc Hosp, Dept Oncol, Harbin, Peoples R China
39.Beijing Canc Hosp, Dept Intervent Radiol, Beijing, Peoples R China
40.Peking Univ First Hosp, Dept Intervent Radiol, Beijing, Peoples R China
41.Beijing Tsinghua Changgung Hosp, Dept Hepatopancreatobiliary Surg, Beijing, Peoples R China
42.Fudan Univ, Dept Liver Surg, Zhongshan Hosp, Shanghai, Peoples R China
43.Chinese Univ Hong Kong, Dept Hepat Biliary Pancreat Surg, Hong Kong, Peoples R China
44.Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiol, Tai An, Shandong, Peoples R China
Recommended Citation
GB/T 7714
Sun, Yongkun,Zhang, Wen,Bi, Xinyu,et al. Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements[J]. LIVER CANCER,2022,11.
APA Sun, Yongkun.,Zhang, Wen.,Bi, Xinyu.,Yang, Zhengqiang.,Tang, Yu.,...&Cai, Jianqiang.(2022).Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.LIVER CANCER,11.
MLA Sun, Yongkun,et al."Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements".LIVER CANCER 11(2022).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Sun, Yongkun]'s Articles
[Zhang, Wen]'s Articles
[Bi, Xinyu]'s Articles
Baidu academic
Similar articles in Baidu academic
[Sun, Yongkun]'s Articles
[Zhang, Wen]'s Articles
[Bi, Xinyu]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Sun, Yongkun]'s Articles
[Zhang, Wen]'s Articles
[Bi, Xinyu]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.